USPTO Examiner MOSELEY II NELSON B - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18810362HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6August 2024May 2025Allow820NoNo
18674612DOSAGE OF CLAUDIN-6 CONJUGATES FOR CANCER TREATMENTMay 2024April 2025Allow1120YesNo
18593028ATP-Dependent Agonists of Immune Cells Function as Anticancer AgentsMarch 2024August 2024Allow500NoNo
183864215-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-2-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow310YesNo
18316628IMMUNOTHERAPY TARGETING TUMOR NEOANTIGENIC PEPTIDESMay 2023August 2024Allow1520YesNo
18057152ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOFNovember 2022March 2025Allow2800YesNo
17983727CANINE PARVOVIRUS NANOBODY CPV-VHH-E3 AND APPLICATION THEREOFNovember 2022May 2023Allow600NoNo
18052738PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSNovember 2022March 2025Allow2800NoNo
18052796PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSNovember 2022May 2025Allow3100NoNo
18051268NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSOctober 2022February 2025Allow2800NoNo
18051225NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSOctober 2022February 2025Allow2700NoNo
18050701NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSOctober 2022April 2025Allow2910NoNo
17959104CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCEROctober 2022July 2023Allow910YesNo
17892460ANTI-CD20 ANTIBODY COMPOSITIONSAugust 2022August 2023Allow1210YesNo
17816114HUMAN MONOCLONAL ANTIBODIES AGAINST YELLOW FEVER VIRUS AND USES THEREFORJuly 2022March 2024Allow1911NoNo
17840655Novel Tri-specific Binding MoleculesJune 2022January 2025Allow3121NoNo
17839754THERAPEUTIC METHODS AND COMPOSITIONSJune 2022June 2025Abandon3610NoNo
17837589Anti-TIGIT AntibodiesJune 2022December 2024Allow3000NoNo
17826295Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITYMay 2022December 2024Allow3111NoNo
17736699BMA031 ANTIGEN BINDING POLYPEPTIDESMay 2022July 2024Allow2721YesNo
17733918DOSING FOR COMBINATION TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-CD79B ANTIBODY DRUG CONJUGATEApril 2022September 2024Allow2821NoNo
17732237ANTI-TUMOR DNA VACCINE WITH PD-1 AND LAG-3 PATHWAY BLOCKADEApril 2022May 2024Abandon2411NoNo
17717464COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A NECTIN-4 TARGETING AGENTApril 2022April 2024Allow2421NoNo
17714912TIGIT- AND LIGHT-BASED CHIMERIC PROTEINSApril 2022August 2024Abandon2801NoNo
17698426NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSMarch 2022May 2022Allow200NoNo
17696799BISPECIFIC AND MONOSPECIFIC ANTIBODIES USING NOVEL ANTI-PD-1 SEQUENCESMarch 2022July 2024Allow2800NoNo
17692315RADIOLABELLED ANTIBODY FRAGMENTS FOR USE IN TREATING CANCERMarch 2022June 2025Allow3920NoNo
17690702HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6March 2022June 2023Allow1500YesNo
17580728VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOFJanuary 2022January 2025Abandon3601NoNo
17580241METHODS FOR TREATING BREAST AND OTHER CANCERS BY TARGETING ARGININOSUCCINATE SYNTHETASE 1-DEFICIENCYJanuary 2022January 2025Abandon3610NoNo
17627540CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCERJanuary 2022February 2025Allow3710YesNo
17561415HIGH-AFFINITY ANTI-MERTK ANTIBODIES AND USES THEREOFDecember 2021December 2024Allow3610NoNo
17645391CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPYDecember 2021December 2024Abandon3610NoNo
17545274COMBINATIONS AND USES THEREOFDecember 2021August 2024Allow3310NoNo
17537837METHODS AND COMPOSITIONS FOR REDUCING METASTASESNovember 2021April 2025Abandon4110NoNo
17534315LAG-3 BINDING MEMBERSNovember 2021August 2024Allow3310NoNo
17533230BINDING MOLECULES BINDING PD-L1 AND LAG-3November 2021November 2024Allow3610NoNo
17531473CYTOKINE PROFILING ANALYSISNovember 2021September 2024Allow3411NoNo
17530510MULTISPECIFIC ANTIGEN BINDING PROTEINSNovember 2021May 2025Abandon4211NoNo
17524894NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSNovember 2021December 2024Abandon3710NoNo
17519192NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERSNovember 2021February 2024Allow2700NoNo
17519436Antibodies binding To HLA-A2/WT1November 2021May 2024Allow3110NoNo
17517994CH3 DOMAIN VARIANT PAIR INDUCING FORMATION OF HETERODIMER OF HEAVY CHAIN CONSTANT REGION OF ANTIBODY AT HIGH EFFICIENCY, METHOD FOR PREPARING SAME, AND USE THEREOFNovember 2021February 2025Allow4010NoNo
17514743PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSOctober 2021January 2024Allow2600NoNo
17514599NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERSOctober 2021March 2024Allow2910NoNo
17515010KITS AND CONTAINERS FOR TREATING VIMENTIN EXPRESSING TUMORSOctober 2021July 2022Allow820NoNo
17510738Tandem Diabody for CD16A-directed NK-cell EngagementOctober 2021December 2024Allow3811YesNo
17503038ANTI-CD38 ANTIBODIES AND METHODS OF USEOctober 2021February 2022Allow400YesNo
17499814ANTI-CD147 ANTIBODYOctober 2021May 2022Allow710NoNo
17498418BIOSYNTHETIC MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATIONOctober 2021May 2025Abandon4311NoNo
17493266NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOFOctober 2021March 2025Allow4121NoNo
17492111NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSOctober 2021January 2022Allow300YesNo
17479776COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINSSeptember 2021October 2022Allow1320YesNo
17446943BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3September 2021April 2025Allow4310NoNo
17466922IGA FC-FOLATE CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCERSeptember 2021August 2024Abandon3501NoNo
17403698BAFF-R ANTIBODIES AND USES THEREOFAugust 2021January 2024Allow2910YesNo
17402068NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERSAugust 2021September 2024Allow3700NoNo
17388059SIGLEC NEUTRALIZING ANTIBODIESJuly 2021July 2024Abandon3501NoNo
17384110Bioengineered Microbial SporesJuly 2021April 2025Abandon4501NoNo
17382305METHODS AND SYSTEMS FOR GENERATING COMPLEX SPATIAL PATTERNSJuly 2021January 2025Allow4210NoNo
17304702BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMAJune 2021November 2024Abandon4111NoNo
17304683BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMAJune 2021June 2024Abandon3501NoNo
17312311Saponin ConjugatesJune 2021January 2025Abandon4410NoNo
17334151COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCERMay 2021February 2025Allow4521YesNo
17324508ANTI-PD-1 ANTIBODIES AND COMPOSITIONSMay 2021February 2024Allow3301NoNo
17318310HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTSMay 2021December 2023Allow3110YesNo
17314492PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERSMay 2021November 2023Allow3010NoNo
17309144ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOFApril 2021May 2025Allow4911NoNo
17290172METHODS FOR PREDICTING A RESPONSE TO BEVACIZUMAB OR PLATINUM-BASED CHEMOTHERAPY OR BOTH IN PATIENTS WITH OVARIAN CANCERApril 2021February 2025Allow4511YesNo
17286437ANTI-CLAUDIN 18.2 AND ANTI-4-IBB BISPECIFIC ANTIBODIES AND USES THEREOFApril 2021December 2021Allow810YesNo
17286406ANTIBODIES AND METHODS FOR TREATMENT OF LYSSAVIRUS INFECTIONApril 2021March 2025Abandon4711NoNo
17232537MULTISPECIFIC ANTIBODIESApril 2021August 2023Allow2800NoNo
17284599Novel method and compounds for treatment of cognitive loss associated with adult onset leukodystrophy with axonal spheroids and pigmented glia (ALSP) and other neurodegenerative diseases involving reduced colony stimulating factor-1 receptor (CSF-1R) signalingApril 2021May 2025Abandon5020NoNo
17228213METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOFApril 2021October 2024Abandon4321YesNo
17284427COMPOSITIONS AND METHODS FOR PREVENTING OR AMELIORATING NEONATAL HSV INFECTIONApril 2021April 2025Allow4821NoNo
17226006METHODS AND COMPOSITIONS FOR TREATING CANCERApril 2021February 2024Abandon3410NoNo
17224431METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATIONApril 2021December 2023Abandon3310NoNo
17210860COMBINATION OF ANTI-PD-1 ANTIBODIES AND BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCERMarch 2021April 2024Allow3720NoNo
17277214CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USEMarch 2021November 2024Allow4411YesNo
17274960MEDICINAL COMPOSITION CONTAINING MONOCLONAL ANTIBODY OR ANTIBODY FAB FRAGMENT THEREOF, AND USE THEREOFMarch 2021August 2024Allow4111NoNo
17250832CANCER TREATMENT WITH 237 CAR-T CELL BASED THERAPEUTICS RECOGNIZING THE TN EPITOPEMarch 2021April 2025Allow4911NoNo
17180110NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOFFebruary 2021September 2021Allow710YesNo
17172577NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSFebruary 2021August 2023Allow3110NoNo
17172621NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSFebruary 2021September 2023Allow3110NoNo
17172252Targeted ImmunotoleranceFebruary 2021July 2024Allow4121NoNo
17161586CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOFJanuary 2021July 2021Allow510NoNo
17148309METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4January 2021July 2023Allow3101NoNo
17143204Bispecific Tetravalent Antibodies and Methods of Making and Using ThereofJanuary 2021May 2025Allow5211NoNo
17140996TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIESJanuary 2021March 2024Abandon3810NoNo
17138279ANTI-CD73 ANTIBODIES AND USES THEREOFDecember 2020October 2023Allow3411NoNo
17138403ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6December 2020August 2023Allow3210NoNo
17138306CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPYDecember 2020November 2023Allow3411YesNo
17134828Glycan-dependent Immunotherapeutic MoleculesDecember 2020January 2023Allow2520YesNo
17135170ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOFDecember 2020January 2024Abandon3701NoNo
17126838FC-REGION VARIANTS WITH MODIFIED FCRN- AND PROTEIN A-BINDING PROPERTIESDecember 2020March 2023Allow2700NoNo
17253286METHOD FOR PRODUCING A CONTROLLED MIXTURE OF TWO OR MORE DIFFERENT ANTIBODIESDecember 2020November 2024Allow4611NoNo
17120935Antibodies Specific for CD47, PD-L1, and Uses ThereofDecember 2020February 2023Allow2611YesNo
17119753ANTI-LY6G6D ANTIBODIES AND METHODS OF USEDecember 2020January 2023Allow2500NoNo
17117969ANTI-TIGIT ANTIBODIES AND USES THEREOFDecember 2020February 2021Allow200YesNo
17108076Modified Cell Expansion and Uses ThereofDecember 2020July 2024Allow4321YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOSELEY II, NELSON B.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
6
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.5%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
45
Allowed After Appeal Filing
8
(17.8%)
Not Allowed After Appeal Filing
37
(82.2%)
Filing Benefit Percentile
18.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MOSELEY II, NELSON B - Prosecution Strategy Guide

Executive Summary

Examiner MOSELEY II, NELSON B works in Art Unit 1642 and has examined 713 patent applications in our dataset. With an allowance rate of 67.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner MOSELEY II, NELSON B's allowance rate of 67.9% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MOSELEY II, NELSON B receive 1.59 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MOSELEY II, NELSON B is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.8% benefit to allowance rate for applications examined by MOSELEY II, NELSON B. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.4% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 59.1% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 76.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 94.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 53% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.